Table 2.
Characteristics of DOX-L, DOX-BTSL, Cypate/DOX-L, and Cypate/DOX-BTSL
| Liposomes | Diameter (nm)a | PDIa | Zeta potential (mV)a | EE (%)b | DL (%)b |
|---|---|---|---|---|---|
| DOX-L | 133.6±2.8 | 0.200±0.003 | −21.6±0.38 | 84.8±2.39 | 6.93±0.89 |
| DOX-BTSL | 126.7±5.2 | 0.095±0.008 | −24.9±0.16 | 91.14±3.0 | 10.3±0.38 |
| Cypate/DOX-L | 156.6±2.0 | 0.098±0.007 | −32.8±0.20 | 84.5±2.60 | 14.47±1.26 |
| Cypate/DOX-BTSL | 156±3.2 | 0.070±0.005 | −26.8±0.09 | 96.8±5.6 | 10.7±0.57 |
Notes:
a
The diameter, PDI, and zeta potential (mean ± SD) measured by DLS three times.
b
EE and DL content of DOX (mean ± SD) determined by fluorescence spectrometer three times.
Abbreviations: DOX, doxorubicin; L, (NH4)2SO4 liposomes; BTSL, bubble-generating thermosensitive liposomes (NH4HCO3); PDI, polydispersity index; EE, entrapment efficiency; DL, drug loading; SD, standard deviation.